Ardelyx (ARDX) Change in Account Payables (2013 - 2026)
Ardelyx (ARDX) reported Change in Account Payables of $9.0 million for Q1 2026, up 493.33% on a YoY basis from $1.5 million in Q1 2025, and up 960.36% quarter-over-quarter from $845000.0 in Q4 2025.
Ardelyx (ARDX) Change in Account Payables (2013 - 2026) Analysis & Trends
Ardelyx has reported Change in Account Payables for 14 years, with the latest figure at $9.0 million in Q1 2026.
- For the quarter ending Q1 2026, Change in Account Payables rose 493.33% year-over-year to $9.0 million; the trailing twelve-month figure through Mar 2026 stood at $14.5 million (up 507.12% YoY), and the FY2025 full-year result was $3.2 million, down 33.46% from the prior year.
- Change in Account Payables for Q1 2026 stood at $9.0 million, up from $845000.0 in the prior quarter.
- The five-year high for Change in Account Payables was $9.0 million in Q1 2026, with the low at -$6.4 million in Q2 2024.
- Historically, Change in Account Payables has averaged $1.4 million across 5 years, with a median of $845000.0 in 2025.
- Annual changes were most pronounced in 2022 — Change in Account Payables surged 55228.57% — and 2023, when it slumped 609.1%.
- Ardelyx's Change in Account Payables stood at $7.7 million in 2022, then tumbled by 56.08% to $3.4 million in 2023, then slumped by 65.43% to $1.2 million in 2024, then slipped by 28.15% to $845000.0 in 2025, then surged by 960.36% to $9.0 million in 2026.
- The last three Change in Account Payables figures came in at $9.0 million (Q1 2026), $845000.0 (Q4 2025), and -$3.3 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -3.26 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 35.60 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -9.42 Mn |
| 10 | Ardelyx | 1.49 Bn | 1.25 Bn | 89.66 Mn | 8.96 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 8.96 Mn |
| Mar 31, 2026 | 8.96 Mn |
| Dec 31, 2025 | 845,000.00 |
| Dec 31, 2025 | 845,000.00 |
| Sep 30, 2025 | -3.30 Mn |
| Sep 30, 2025 | -3.30 Mn |
| Jun 30, 2025 | 7.96 Mn |
| Jun 30, 2025 | 7.96 Mn |
| Mar 31, 2025 | -2.28 Mn |
| Mar 31, 2025 | -2.28 Mn |
| Dec 31, 2024 | 1.18 Mn |
| Dec 31, 2024 | 1.18 Mn |
| Sep 30, 2024 | 3.94 Mn |
| Sep 30, 2024 | 3.94 Mn |
| Jun 30, 2024 | -6.40 Mn |
| Jun 30, 2024 | -6.40 Mn |
| Mar 31, 2024 | 6.14 Mn |
| Mar 31, 2024 | 6.14 Mn |
| Dec 31, 2023 | 3.40 Mn |
| Dec 31, 2023 | 3.40 Mn |